Ryan Baron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Baron has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Faraz Amzajerdian
Department of Radiology University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications - Hooman Hamedani
Radiology, University of Pennsylvania, Philadelphia, PA, United States
4 shared publications - Kai Ruppert
Department of Radiology University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications - L. Loza
Radiology, University of Pennsylvania, Philadelphia, PA, United States
3 shared publications M.K. Ismail
Radiology, University of Pennsylvania, Philadelphia, PA, United States
3 shared publicationsR.R. Rizi
Radiology, University of Pennsylvania, Philadelphia, PA, United States
3 shared publications
Latest Publications
- 30 April 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (6) , 1691-1707
Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma
Background and Aims: Metabolic inhibitors have demonstrated limited efficacy for cancer therapy due to metabolic plasticity and systemic toxicity. Locoregional therapies (LRT), such as transarterial embolization (TAE) or transarterial chemoembolization (TACE), generate ischemic stress that reprograms the tumor microenvironment (TME) toward glycolytic dependency, creating an opportunity to sensitize hepatocellular carcinoma (HCC) to metabolic inhibition. This study investigated whether pharmacologic inhibition of lactate dehydrogenase (LDH) with NCATS-SM1441 could exploit TAE-induced metabolic vulnerabilities to improve therapeutic efficacy in HCC. Approach and Results: Human HCC cell lines were exposed to replete or ischemic (TAE-like) conditions and treated with the LDH inhibitor NCATS-SM1441. Glucose/lactate flux, adenosine triphosphate (ATP) levels, and viability were assessed. In vivo, a diethylnitrosamine (DEN)-induced rat HCC model was treated with intra-arterial NCATS-SM1441, TAE, or their combination. Drug distribution, tumor metabolism, necrosis, and survival were analyzed using mass spectrometry imaging, histopathology, T2-weighted magnetic resonance imaging (MRI), and survival metrics. Ischemic conditions induced LDHA expression and glycolytic flux, enhancing susceptibility to LDH inhibition. The combination of intra-arterial NCATS-SM1441 before embolization increased intratumoral drug accumulation, reduced systemic exposure, and synergized with TAE to suppress lactate production, promote tumor necrosis, and significantly extend local progression-free survival. Conclusions: TAE conditions the TME to create a therapeutically targetable glycolytic dependency. Combining TAE with LDH inhibition overcomes key limitations of metabolic inhibitors as monotherapies, enhancing local control and survival with minimal systemic toxicity, supporting integration of metabolism-targeted agents with LRT for unresectable HCC.
- 30 April 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (6) , 1691-1707
Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma
Background and Aims: Metabolic inhibitors have demonstrated limited efficacy for cancer therapy due to metabolic plasticity and systemic toxicity. Locoregional therapies (LRT), such as transarterial embolization (TAE) or transarterial chemoembolization (TACE), generate ischemic stress that reprograms the tumor microenvironment (TME) toward glycolytic dependency, creating an opportunity to sensitize hepatocellular carcinoma (HCC) to metabolic inhibition. This study investigated whether pharmacologic inhibition of lactate dehydrogenase (LDH) with NCATS-SM1441 could exploit TAE-induced metabolic vulnerabilities to improve therapeutic efficacy in HCC. Approach and Results: Human HCC cell lines were exposed to replete or ischemic (TAE-like) conditions and treated with the LDH inhibitor NCATS-SM1441. Glucose/lactate flux, adenosine triphosphate (ATP) levels, and viability were assessed. In vivo, a diethylnitrosamine (DEN)-induced rat HCC model was treated with intra-arterial NCATS-SM1441, TAE, or their combination. Drug distribution, tumor metabolism, necrosis, and survival were analyzed using mass spectrometry imaging, histopathology, T2-weighted magnetic resonance imaging (MRI), and survival metrics. Ischemic conditions induced LDHA expression and glycolytic flux, enhancing susceptibility to LDH inhibition. The combination of intra-arterial NCATS-SM1441 before embolization increased intratumoral drug accumulation, reduced systemic exposure, and synergized with TAE to suppress lactate production, promote tumor necrosis, and significantly extend local progression-free survival. Conclusions: TAE conditions the TME to create a therapeutically targetable glycolytic dependency. Combining TAE with LDH inhibition overcomes key limitations of metabolic inhibitors as monotherapies, enhancing local control and survival with minimal systemic toxicity, supporting integration of metabolism-targeted agents with LRT for unresectable HCC.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3923
Metabolic Changes in Donor Lung During Ischemia as a Function of Time and Temperature
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3923
Metabolic Changes in Donor Lung During Ischemia as a Function of Time and Temperature
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A2292
Improved Dynamic Micro-CT Imaging Binning for Optimized Image Reconstruction
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A2292
Improved Dynamic Micro-CT Imaging Binning for Optimized Image Reconstruction
- 14 July 2021
- Published by Elsevier in Academic Radiology
- Vol. 29 (Suppl 2) , S127-S136
Deriving Regionally Specific Biomarkers of Emphysema and Small Airways Disease Using Variable Threshold Parametric Response Mapping on Volumetric Lung CT Images
- 14 July 2021
- Published by Elsevier in Academic Radiology
- Vol. 29 (Suppl 2) , S127-S136
Deriving Regionally Specific Biomarkers of Emphysema and Small Airways Disease Using Variable Threshold Parametric Response Mapping on Volumetric Lung CT Images